Fresenius Kabi’s denosumab biosimilar filing has been accepted by the European Medicines Agency, coming hot on the heels of a US submission.

Fresenius Kabi has become the first firm to market a subcutaneous tocilizumab biosimilar in the US, introducing an SC version of its Tyenne rival to Actemra just a couple of months after the intravenous launch.

At a high-profile panel closing out Medicines for Europe’s 30th annual conference in Dublin, six industry leaders set out their views on key topics including pricing, regulation, sustainability, and stakeholder communication.

A busy couple of weeks for executive appointments in the generics and biosimilars industry has seen Dr Reddy’s name a new North American CEO, Fresenius Kabi appoint a new biopharma chief, Teva recruit a new head of global operations, and more.